Daré Bioscience, Inc. Appoints Jessica Grossman as Class I Independent Director
April 11, 2018 at 06:06 am EDT
Share
Daré Bioscience, Inc. announced that on April 9, 2018, the board of directors of the company, upon recommendation of it's Nominating and Corporate Governance Committee (the N&CG Committee), increased the size of the Board from five directors to six directors and elected Jessica Grossman, M.D. to fill the vacancy created by such increase. The increase in the size of the Board and the election of Dr. Grossman became effective on April 9, 2018. Dr. Grossman was elected as a Class I director whose term expires at the company's 2018 annual meeting of stockholders, expected to be held in July, 2018. The board determined that Dr. Grossman is as an independent director under Rule 5605(a)(2) of the Nasdaq Listing Rules. Immediately following Dr. Grossman's election to the Board, the board appointed her as a member of the N&CG Committee and Roger Hawley resigned from his position as a member of the N&CG Committee. The N&CG Committee is presently composed of Susan L. Kelley, M.D. as Chairperson and Dr. Grossman as a member. Dr. Grossman currently serves as the Chief Executive Officer of Medicines360.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARÉ BIOSCIENCE, INC. 
